Xiang-Hua Fu Selected Research

anisodamine

1/2019	Comparison of myocardial microcirculatory perfusion after catheter-administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST-elevation myocardial infarction.
10/2012	Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
4/2008	[Effect of intra-coronary injection of anisodamine on the slow-reflow phenomenon in patients with acute myocardial infarction after percutaneous coronary intervention].
7/2007	Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiang-Hua Fu Research Topics

Disease

8	Myocardial Infarction 01/2019 - 07/2007
6	ST Elevation Myocardial Infarction 01/2019 - 08/2012
4	Cardiovascular Diseases (Cardiovascular Disease) 05/2015 - 08/2012
4	Infarction (Infarctions) 07/2014 - 07/2007
3	Acute Coronary Syndrome 01/2017 - 03/2009
2	Thrombosis (Thrombus) 01/2019 - 08/2013
2	No-Reflow Phenomenon 08/2013 - 03/2009
2	Cardiac Arrhythmias (Arrythmia) 04/2008 - 07/2007
1	Heart Failure 11/2019
1	Pathologic Constriction (Stenosis) 01/2017
1	Reperfusion Injury 05/2015
1	Hemorrhage 07/2014
1	Hyperlipidemias (Hyperlipidemia) 07/2014
1	Death (Near-Death Experience) 01/2014
1	Type 2 Diabetes Mellitus (MODY) 10/2012
1	Diabetic Nephropathies (Diabetic Nephropathy) 10/2012
1	Glomerulonephritis 10/2012
1	Renal Insufficiency (Renal Failure) 10/2012
1	Tachycardia (Tachyarrhythmias) 04/2008
1	Bradycardia 07/2007
1	Spasm (Spasms) 07/2007
1	Hypotension (Low Blood Pressure) 07/2007

Drug/Important Bio-Agent (IBA)

4	anisodamineIBA 01/2019 - 07/2007
3	N(2)-(3-trifluoromethylphenyl)guanineIBA 01/2019 - 03/2009
3	S- (2- chloro- 1,1,2- trifluoroethyl)cysteine (CTFC)IBA 05/2015 - 03/2009
3	omega-Chloroacetophenone (Mace)IBA 05/2015 - 08/2012
1	Simendan (Levosimendan)IBA 11/2019
1	saruplaseIBA 01/2019
1	pitavastatin (itavastatin)FDA Link 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	Alprostadil (Muse)FDA LinkGeneric 05/2015
1	Pharmaceutical PreparationsIBA 05/2015
1	Cytochromes c (Cytochrome c)IBA 01/2014
1	Creatine Kinase (Creatine Phosphokinase)IBA 08/2013
1	Tirofiban (Aggrastat)FDA Link 08/2013
1	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 08/2013
1	Sodium Chloride FDA LinkGeneric 10/2012
1	Radioisotopes (Radionuclides)IBA 01/2012
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2009
1	CholesterolIBA 03/2009
1	Dihydrotachysterol (AT 10)IBA 04/2008
1	Nitroglycerin (Dynamite)FDA LinkGeneric 07/2007

Therapy/Procedure

12	Percutaneous Coronary Intervention 01/2019 - 07/2007
2	Catheters 01/2019 - 08/2013
2	Therapeutics 01/2017 - 10/2012
1	Intravenous Administration 05/2015
1	Length of Stay 07/2014
1	Stents 03/2009